From: Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
 |  |  |  |  | Values in AD patients |  | ||
---|---|---|---|---|---|---|---|---|
Study | Subjects | Mean age (years) | Platform and antibodies | CV | Aβ1-40 | Aβ1-42 | Aβ1-42/Aβ1-40 | Other |
Mehta et al. 2000 [55] | 61 CN 78 AD | 67 74 | ELISA 6E10 R162 R164 | <18% | ↑ | = | - |  |
Mayeux et al. 2003 [27] | 79 AD 365 CN | 83.2 75.5 | ELISA 6E10 R182 R165 | - | = | ↑ | NA |  |
Fukumoto et al. 2003 [26] | 92 CN 96 PD 37 MCI 146 AD | 69 66.0 72.6 76 | ELISA Takeda | <10% | = | = | = | Â |
Assini et al. 2004 [41] | 72 CN 88 MCI | 73 75 | ELISA IBL | - | - | - | - | Increased Aβ1-42 in MCI women |
Lewczuk et al. 2010 [56] | 137 MCIp 62 MCI-OD 127 AD 25 OD | 67.4 63.3 70.8 66.6 | xMAP INNO-BIA | <10% | - | - | - | MCI and AD with AD-like CSF ↓ Aβ1-42 & ↓ Aβ1-42/Aβ1-40 |
Lui et al. 2010 [14] | 724 CN 122 MCI 186 AD | 70.0 75.9 78.6 | ELISA Mehta xMAP INNO-BIA | - | = | ↓ | = |  |
Le Bastard et al. 2010 [12] | 47 CN 50 non-AD 47 AD | 69 74 82 | xMAP INNO-BIA | <10% | = | = | = | ↓ Aβ1-42/AβN-42 |
187 CNs 10 CNp 162 MCIs 145 MCIp 162 AD | 75.8 78.4 74.7 74.6 75.3 | xMAP INNO-BIA | <10% | = | = | = | Interaction between age and diagnosis defined by CSF |